Patrick Amstutz

Outlook Microsoft Office 365 Adobe Media Optimizer Mobile Friendly Google Font API Typekit WordPress.org Google Tag Manager Vimeo Nginx AI

darpins oncology immunooncology radiopharmaceuticals immunology & other indications virology ophthalmology intellectual property of darpins repeat proteins & protein engineering collaborations with other leading pharmaceutical companies biotechnology life sciences biotechnology: biological products (no diagnostic substances) health care biotechnology research darpin therapeutics cancer treatment multispecific targeted therapies immune cell engagers precision medicine radio-darpin therapy drug discovery bacterial fermentation tissue penetration high specificity customized drugs solid tumor treatment pharmaceutical development clinical trials multifunctional drugs immune system activation protein therapeutics avidity-driven targeting modular therapeutics viral neutralization covid-19 treatment sars-cov-2 cancer immunotherapy biotech partnerships selective targeting drug design therapeutic window safety profile patient outcomes targeted drug delivery preclinical studies high-affinity binders multiplexing biologics gene therapy cancer biology t cell engagement biological challenges fresh therapeutic solutions cutting-edge technology drug candidates half-life extension therapeutic strategy innovative delivery systems clinical development pharma collaborations biopharmaceutical darpin therapeutics immuno-oncology small-protein therapeutics custom-built drugs strategic partnerships innovative therapeutics patient impact research & development pharmaceutical collaborations healthcare providers serious diseases tumor-specific delivery co-development agreements therapeutic innovation unmet medical needs drug modalities cancer patients therapeutic candidates collaboration breakthrough therapies patient-focused solutions healthcare market global partnerships financial stability clinical-stage company hospital & health care health wellness & fitness